CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING ANTIRETROVIRAL THERAPY ADMINISTERED EVERY 2-MONTHS IS COST EFFECTIVE FOR THE TREATMENT OF HIV-1 IN SPAIN

被引：0
|
作者：
Moreno Guillen, S. [1 ]
Rivero, A. [2 ]
Ventayol, P. [3 ]
Falco, V. [4 ]
Torralba, M. [5 ]
Schroeder, M. [6 ]
Neches, V. [7 ]
Vallejo-Aparicio, L. A. [7 ]
Mackenzie, I. [8 ]
Turner, M. [9 ]
Harrison, C. [9 ]
机构：
[1] Hosp Ramon & Cajal, Madrid, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Hosp Univ Son Espases, Palma De Mallorca, Spain
[4] Hosp Valle De Hebron, Barcelona, Spain
[5] Hosp Univ Guadalajara, Guadalajara, Spain
[6] ViiV Healthcare, Brentford, England
[7] GSK, Tres Cantos, Spain
[8] Hlth Econ & Outcomes Res Ltd, Stratford Upon Avon, War, England
[9] Hlth Econ & Outcomes Res Ltd, Cardiff, Crf, Wales
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE345
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [21] Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
    Swindells, Susan
    Lutz, Thomas
    Van Zyl, Lelanie
    Porteiro, Norma
    Stoll, Matthias
    Mitha, Essack
    Shon, Alyssa
    Benn, Paul
    Huang, Jenny O.
    Harrington, Conn M.
    Hove, Kai
    Ford, Susan L.
    Talarico, Christine L.
    Chounta, Vasiliki
    Crauwels, Herta
    Van Solingen-Ristea, Rodica
    Vanveggel, Simon
    Margolis, David A.
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Spreen, William R.
    AIDS, 2022, 36 (02) : 185 - 194
  • [22] Cost-utility analysis of long-acting cabotegravir plus rilpivirine for the treatment of HIV infection in the United Kingdom
    Parker, B.
    Chounta, V.
    Gait, C.
    Hayward, O.
    Hunjan, M.
    Schroeder, M.
    Jacob, I.
    Van de Velde, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 37 - 37
  • [23] Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine
    Rubenstein, Emma
    Diemer, Myriam
    Goldwirt, Lauriane
    Lascoux-Combe, Caroline
    Chaix, Marie-Laure
    Rami, Agathe
    Ponscarme, Diane
    Lafaurie, Matthieu
    Denis, Blandine
    De Castro, Nathalie
    Gras, Julien
    Liegeon, Geoffroy
    Sellier, Pierre-Olivier
    Deville, Laure
    Chevret, Sylvie
    Delaugerre, Constance
    Molina, Jean-Michel
    AIDS, 2024, 38 (08) : 1267 - 1269
  • [24] Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
    Howe, Zach W.
    Norman, Sarah
    Lueken, Abbie F.
    Huesgen, Emily
    Farmer, Eric K.
    Jarrell, Kaitlyn
    Mathis, Joscelyn E.
    Bonham, Kyle W.
    Hahn, Julie
    PHARMACOTHERAPY, 2021, 41 (08): : 686 - 699
  • [25] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
    Orkin, C.
    Oka, S.
    Philibert, P.
    Brinson, C.
    Bassa, A. C.
    Gusev, D.
    Degen, O.
    Gonzalez Garcia, J.
    D'Amico, R.
    Dorey, D.
    Griffith, S.
    Margolis, D. A.
    St Clair, M.
    Williams, P.
    Spreen, W. R.
    HIV MEDICINE, 2020, 21 : 14 - 14
  • [26] Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
    Chounta, Vasiliki
    Overton, Edgar T.
    Mills, Anthony
    Swindells, Susan
    Benn, Paul D.
    Vanveggel, Simon
    van Solingen-Ristea, Rodica
    Wang, Yuanyuan
    Hudson, Krischan J.
    Shaefer, Mark S.
    Margolis, David A.
    Smith, Kimberly Y.
    Spreen, William R.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (06): : 849 - 862
  • [27] Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
    Mills, Anthony
    Richmond, Gary J.
    Newman, Cheryl
    Osiyemi, Olayemi
    Cade, Jerry
    Brinson, Cynthia
    De Vente, Jerome
    Margolis, David A.
    Sutton, Kenneth C.
    Wilches, Viviana
    Hatch, Sarah
    Roberts, Jeremy
    McCoig, Cynthia
    Garris, Cindy
    Vandermeulen, Kati
    Spreen, William R.
    AIDS, 2022, 36 (02) : 195 - 203
  • [28] Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy
    Kurtis Moffatt
    Ismaiel A. Tekko
    Lalitkumar Vora
    Fabiana Volpe-Zanutto
    Aaron R. J. Hutton
    Jessica Mistilis
    Courtney Jarrahian
    Nima Akhavein
    Andrew D. Weber
    Helen O. McCarthy
    Ryan F. Donnelly
    Pharmaceutical Research, 2023, 40 : 1673 - 1696
  • [29] Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
    Vasiliki Chounta
    Edgar T. Overton
    Anthony Mills
    Susan Swindells
    Paul D. Benn
    Simon Vanveggel
    Rodica van Solingen-Ristea
    Yuanyuan Wang
    Krischan J. Hudson
    Mark S. Shaefer
    David A. Margolis
    Kimberly Y. Smith
    William R. Spreen
    The Patient - Patient-Centered Outcomes Research, 2021, 14 : 849 - 862
  • [30] Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: Results from the Dutch ATHENA national observational cohort
    Jongen, V.
    Wit, F.
    van Eeden, A.
    Brouwer, A.
    Soetekouw, R.
    El Moussaoui, R.
    Stalenhoef, J.
    Sigaloff, K.
    Mudrikova, T.
    Gisolf, J.
    Wensing, A.
    van der Valk, M.
    HIV MEDICINE, 2023, 24 : 167 - 169
12345